Nanodrugs have been widely investigated and developed in order to significantly improve the safety profile and efficacy of existing drugs (which is usually achieved by incorporating the various nanometer supports) or the development of new molecules of active substances to a certain extent achieved by targeted action (the so-called polymer therapeutics). Research and industrial activities related to the development of nanodrugs are very intense in developed countries. Analyzing the total number of publications, patents and nanodrugs approved for use are observed significant differences between the US and Europe. The analysis results in Europe clearly indicate that the present activities primarily focused on research of nanodrugs as the EU forefront in the number of publications, and less on their commercialization. Thus, within the EU, Germany, UK and France have the most publications. In contrast, the US are leading in the number of patents, which indicates that the activities of the United States focused on the commercialization of nanodrugs. Innovations in the field of nanodrugs have mostly related to small and medium enterprises, while big pharmaceutical companies show relatively less interest until it clearly shows the economic potential. In the area of EU companies that develop nanodrugs are predominantly located nearby research institutes because in this way they ensure conditions for their successful cooperation. Thesis clearly describes the company's activities in the field of nanodrugs. Screening and presentation of the company is largely based on the companies of the European Economic Area.